The Scalpel's Edge

Dr. Tim Sayed walks through a recently accepted study from the Journal of Clinical Oncology Practice showing that GLP-1 medications like Ozempic, Mounjaro, and Zepbound are associated with a significant reduction in breast cancer incidence in overweight women. The paper, led by researchers at the University of Pennsylvania, analyzed electronic health records from roughly 111,000 women ages 45 to 8...

Dr. Tim Sayed walks through a recent New York Times article on food noise — the persistent mental chatter about eating that many people with obesity describe as relentless — and what GLP-1 medications like semaglutide and tirzepatide appear to do to quiet it. Drawing on both his clinical experience prescribing these medications and his own personal use of them, Sayed unpacks the concept of the set...

Dr. Tim Sayed walks through an April 2026 study published in Nature that analyzed over 410,000 Reddit posts from people using semaglutide and tirzepatide, using AI language models to extract and categorize what patients were actually saying about their experiences on these medications. The study identified roughly 67,000 self-reporting users, and among them, 43.5% described at least one side effec...

Dr. Tim Sayed speaks with Rachel Blogg, a licensed psychotherapist and athlete who spent roughly three and a half years navigating breast augmentation, multiple revisions, capsular contracture, implant malposition, and eventually explant surgery before finding relief from symptoms she hadn't initially connected to her implants at all. Rachel's account moves through the full arc — from he...

Dr. Tim Sayed opens with a published personal account from a 56-year-old runner and author who had saline implants placed in the early 2000s and chose, two decades later, to have them removed and stay flat. The story moves through familiar territory for explant patients — the original decision made from insecurity, the body changes that followed breastfeeding, the capsular contracture that eventua...

Dr. Tim Sayed takes a closer look at the latest shift in medically supervised weight loss with the FDA approval of an oral GLP-1 medication. After years of injections dominating the space, a once daily pill introduces a new layer of accessibility, convenience, and patient choice. He walks through how these medications actually work in the body, from slowing gastric emptying to quieting food noise,...

Dr. Tim Sayed takes a thoughtful look at newly published data from the Achieve 3 trial, a 52-week head-to-head study comparing Eli Lilly’s investigational oral GLP-1, orforglipron, to oral semaglutide in adults with type 2 diabetes not adequately controlled on metformin. Published in The Lancet , the study showed greater A1C reduction and more weight loss at higher doses of orforglipron, with impr...

On The Scalpel’s Edge , Dr. Tim Sayed takes a clear-eyed look at where GLP-1 weight loss medications are headed and why the landscape feels so unsettled right now. From the FDA’s latest move against compounded GLP-1 drugs to the rise of direct-to-consumer platforms and the new TrumpRX pricing model, this is an honest, surgeon-level reflection on access, affordability, and control. Dr. Sayed shares...

Dr. Tim Sayed walks through some recent developments in the GLP-1 space that raise a question almost everyone on these medications eventually asks. What happens when you stop. He reflects on new data around weight regain after discontinuing GLP-1 drugs, including a large meta-analysis showing how quickly weight and metabolic markers tend to return toward baseline once the medication is stopped. He...

On The Scalpel’s Edge, Dr. Tim Sayed talks with Elizabeth Everett about her experience with breast implant illness and what it was like to spend years feeling dismissed while her body kept sending louder and louder signals. She shares why she chose implants after having her third son, how symptoms slowly built over time, and the way stress, hormones, and a foreign body in her system seemed to crea...

In this episode of The Scalpel’s Edge, Dr. Tim Sayed takes a deep dive into the latest research on GLP1 medications and the lesser known side effects patients may experience. Drawing from new studies, clinical insights, and his own experience with GLP1 therapy, Dr. Sayed breaks down how these medications may influence anemia risk, micronutrient deficiencies, appetite changes, and overall metabolic...

In this episode of The Scalpel’s Edge, Dr. Tim Sayed takes listeners inside the world of personalized genetic testing and how it can transform perioperative planning for explant patients and anyone seeking deeper insight into their inflammatory health. Dr. Sayed breaks down the SHARP program’s integrated approach, which combines genomic testing, supplements, psychological support, and lifestyle gu...

Explore the growing movement of breast implant removal as Dr. Tim Sayed breaks down why twenty four well known celebrities decided to explant. In this powerful episode of The Scalpel’s Edge, Dr. Sayed explains the emotional, physical, and aesthetic reasons behind their decisions and highlights the rising awareness around breast implant illness, autoimmune symptoms, and personal identity. He also s...

A new era of weight management is on the horizon. In this episode of The Scalpel’s Edge , learn how oral GLP-1 medications like semaglutide (Rebelsus) are changing the landscape of obesity care and cardiovascular health. Explore key findings from the OASIS-4 Phase 3 trial, new FDA updates, and what the data reveals about blood sugar control, heart health, and weight reduction across all age groups...

In this episode of The Scalpel’s Edge, Dr. Tim Sayed reviews a newly published study from Colombia examining outcomes in women with breast implant illness following explant surgery. With over 125 patients and 18 months of follow-up, this research reveals significant improvements in symptoms such as joint pain, fatigue, and hair loss — and offers valuable insight into the science, skepticism, and e...

In this episode of The Scalpel’s Edge , Dr. Tim Sayed breaks down a recent CNN feature on the growing movement around explant surgery and breast implant illness. From celebrity testimonials like Alyssa Milano’s to the troubling stories of patients who felt pressured by surgeons, Dr. Sayed dives deep into what’s driving the rise in breast implant removals. He explores the science, the stigma, and t...

In this episode of The Scalpel’s Edge, Dr. Tim Sayed takes a deep dive into the shifting regulatory landscape for compounded GLP1 medications and what recent FDA warning letters mean for providers, pharmacies, and patients. He also reviews promising new clinical trial data on Pfizer’s experimental drug MET97, which may offer greater weight loss with fewer side effects compared to current options....

On this episode of The Scalpel’s Edge we explore a fascinating new study showing how GLP1 medications like semaglutide and tirzepatide may not only improve heart failure outcomes but also reduce greenhouse gas emissions. As I break down this meta-analysis presented at the European Society of Cardiology Congress you will hear how these drugs can deliver benefits for individual patients while also c...

In this episode of The Scalpel’s Edge, Dr. Tim Sayed examines one of the most debated topics in plastic surgery, breast implant illness. He reviews findings from a arecent cohort study published in Cureus while also drawing from his experience as a double board certified plastic surgeon. The discussion explores patient outcomes after explant surgery, the role of inflammation, and the balance betwe...

On this episode of The Scalpel’s Edge , I’m diving into a fascinating new study that compares GLP-1 drugs like tirzepatide to traditional testosterone replacement therapy in men with obesity and low testosterone function. The results? Pretty eye-opening. We’ll break down how these medications - originally developed for weight loss and diabetes - are now showing promise in naturally improving testo...

In this episode of The Scalpel’s Edge, Dr. Tim Sayed breaks down compelling new research on GLP1 medications like semaglutide, tirzepatide, and the latest entrant, ecnoglutide. With real-world data from Cleveland Clinic and insights from an international Phase 3 trial, Dr. Sayed explores how these medications are performing outside of clinical trials, what happens after patients stop taking them,...

In this episode of The Scalpel’s Edge, Dr. Tim Sayed shares an inside look at a new chapter in his practice. The SHARP Program, also known as the Strategic Holistic Accelerated Recovery Program, was developed by Dr. Robert Whitfield to support explant patients through personalized wellness and recovery. Dr. Sayed walks through the details of his own participation in the program, breaking down the...

In this solo episode, Dr. Tim Sayed takes listeners behind the scalpel to explore a topic that’s both controversial and critical: breast implant illness (BII). With honesty and compassion, he unpacks the common symptoms that may indicate a deeper issue—from chronic fatigue and joint pain to unexplained anxiety—and how continuous exposure to implants may trigger systemic inflammation in the body. H...

What if science could validate what thousands of women have already reported? In this episode of The Scalpel’s Edge , Dr. Tim Sayed unpacks a newly published study in Nature Portfolio that may mark a turning point in how we understand breast implant illness (BII). The study reveals a statistically significant spike in FGF-19—a critical metabolic and healing biomarker—after explant surgery, reinfor...

In this powerful episode of The Scalpel’s Edge , Dr. Tim Sayed, a double board-certified plastic surgeon and holistic wellness expert, dives deep into the intersection of science, spirituality, and self-discipline. Using his own experience with Ramadan fasting as a lens, Dr. Sayed unpacks the compelling health benefits of intermittent fasting — from fat loss and improved metabolic markers to enhan...